Adams Clinical, LLC, a leading Neuroscience-focused clinical trial site network announced today that it has agreed on terms of the intent to partner with InSite Clinical Research (“InSite”), a clinical trial site in the Dallas-Fort Worth metroplex with expertise in inpatient and outpatient clinical trials for psychiatric and neurologic illnesses, including Schizophrenia.
“InSite adds an important dimension to our business as it expands Adam’s disease area expertise and marks the Company’s entry into Texas”
HealthTech Insights: Everise Expands and Diversifies Its Healthcare Services Portfolio With the Acquisition of Continuum Global Solutions’ Vertical
In parallel with this partnership, Adams Clinical is expanding inpatient capabilities to its existing Watertown, MA and Bronx, NY sites. The Company expects both locations to begin screening inpatient participants in the first half of 2025, augmenting Adams’ market-leading capabilities in outpatient Psychiatry and Alzheimer’s Disease treatment and prevention trials.
“InSite adds an important dimension to our business as it expands Adam’s disease area expertise and marks the Company’s entry into Texas,” said Nelson Rutrick, CEO of Adams Clinical. “Historically, Adams Clinical focused only on Depression, outpatient Psychiatry, and Alzheimer’s Disease. Dr. Shiwach and the entire InSite team are widely regarded by pharmaceutical and biotech industry sponsors as a leader in acute Schizophrenia, Bipolar Disorder and Substance Use Disorder research. Dr. Shiwach and InSite are well-known for their contributions in many successful clinical trials that have led to new drug approvals over the last 20 years.”
HealthTech Insights: EquipX Announces Collaboration with Vizient to Optimize Healthcare Equipment Fleet
Mehran Ahmed, Partner at InTandem Capital Partners, added, “InSite has developed a strong track record in finding participants in this growing therapeutic area and we are excited to partner with InSite to further enhance their capabilities.”
“I am delighted to join the Adams Clinical network and bring opportunities for additional clinical trials to the diverse psychiatric and neurological patient population that we serve here in Texas,” said Dr. Raj Shiwach, Principal Investigator at InSite. “I look forward to sharing my clinical expertise to replicate our successful inpatient Schizophrenia trial delivery model in the Massachusetts and New York locations.”
HealthTech Insights: Carestream Secures Crucial Business Partner Agreement in Algeria
Dr. Steve Brannan, an industry veteran in Schizophrenia drug development who most recently led the clinical development and successful FDA submission of Cobenfy (xanomeline & trospium chloride, formerly known as KarXT) as Chief Medical Officer of Karuna Therapeutics, said, “Dr. Shiwach made a substantial enrollment contribution in our Phase 2 and 3 KarXT trials. There continues to be an enormous unmet need for effective new therapies for people living with Schizophrenia and other psychiatric illnesses. The many promising new treatments in development across industry will necessitate an increase in clinical research sites capable of conducting high-quality inpatient and outpatient Psychiatry trials for the foreseeable future. The acquisition of InSite and the establishment of inpatient units at the existing Boston and New York City locations underscores Adams Clinical’s strategic alignment with the needs and priorities of their pharmaceutical and biotech sponsor customers.”
HealthTech Insights: Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics
The partnership with InSite follows a series of strategic expansion steps Adams Clinical has undertaken in 2024, including doubling existing site capacity with the opening of new site locations in New York City with Davis Clinical in the Bronx and Berman Clinical in Harlem.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – businesswire
